Reading BIOA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIOA free→Reading BIOA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIOA free→QuarterlyIQ Insights · BIOA
Price, valuation, and the composite score on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $18.04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| Peer EV/Sales | 12M | $7.68 | 9.2 | 0.22 | TTM | high |
Monthly trailing P/E with quartile reference lines.
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.